Stocks · Healthcare · Biotechnology
Century Therapeutics, Inc. IPSC
$1.53 -4.97% Close, Oct 2, 2026 · NASDAQ · Market cap $277.0M
Expensive vs sectorHigh risk
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 138.6% in a year.
- Over the past year the stock returned +206.1%, ahead of the S&P 500 by 191.1 percentage points.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
- Revenue growth, 3-year CAGRTop 4%
- Revenue growth accelerationTop 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 30%
- Accruals (lower is better)Top 42%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 11%
- Free-cash-flow yieldBottom 15%
- EBITDA / enterprise valueBottom 19%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 3%
- 6-month returnBottom 18%
- 1-year return vs S&P 500Top 5%
- Distance from 52-week highBottom 29%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 42%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 49%
- Upside to consensus price targetTop 7%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 50%
- Maximum drawdown, 3 yearsBottom 10%
- Beta vs S&P 500 (lower is better)Bottom 20%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -100.0% | -100.0% | → |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | -100.0% | → | Bottom 2% |
| Return on invested capital | -43.7% | — | Bottom 30% | |
| Revenue growth, 3-year CAGR | 175.9% | — | Top 4% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -8.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +0.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.29%
- Shareholder yield
- -0.29%
- Share count change, 1 year
- +138.6%
- Share count change, 3-year CAGR
- +51.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +0.2%
- Average 2-day reaction, last 8
- -2.2%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $7.50
- Target vs current price
- +390.2%
- Analysts with a rating
- 9
- Share rating Buy or Strong Buy
- 78%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | -54.5% | -4.9% | -4.9% | -1.5% | — |
| May 13, 2026 | +26.7% | -0.4% | -7.4% | -7.4% | -12.7% |
| Mar 12, 2026 | +10.7% | -8.4% | -15.8% | -17.2% | -22.0% |
| Nov 13, 2025 | +17.9% | -17.5% | -8.2% | +5.0% | +242.6% |
| Aug 14, 2025 | +0.0% | +3.2% | +2.2% | -2.8% | +1.3% |
| May 15, 2025 | +387.1% | +5.8% | +18.5% | +22.7% | +0.1% |
| Mar 19, 2025 | +4.4% | -0.9% | -5.7% | -14.8% | +2.0% |
| Nov 5, 2024 | +19.6% | +5.6% | +16.7% | +23.0% | -38.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.17 | -$0.11 | -54.5% | — |
| May 13, 2026 | -$0.11 | -$0.15 | +26.7% | — |
| Mar 12, 2026 | -$0.25 | -$0.28 | +10.7% | — |
| Nov 13, 2025 | -$0.32 | -$0.39 | +17.9% | — |
| Aug 14, 2025 | -$0.38 | -$0.38 | +0.0% | — |
| May 15, 2025 | $0.89 | -$0.31 | +387.1% | $109.2M |
| Mar 19, 2025 | -$0.43 | -$0.45 | +4.4% | $4.2M |
| Nov 5, 2024 | -$0.37 | -$0.46 | +19.6% | $791,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -31.95% | — | — | Bottom 15% |
| Earnings yield | -67.97% | — | — | Bottom 11% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -8.5%
- 200-day average slope (20 days)
- +6.7%
- Distance from 50-day average
- -21.9%
- Distance from 200-day average
- -26.1%
- RSI (14)
- 27.7
- Relative volume
- 1.60×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 55.9%
- Volatility vs own 5-year history
- 13th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.80
- Correlation with S&P 500
- 0.25
- Current drawdown from 1-year high
- -48.0%
- Maximum drawdown, 3 years
- -92.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Aug 13, 2021 | Apr 8, 2025 | -98.8% | 916 days | Not yet recovered |
| Jun 22, 2021 | Jun 25, 2021 | -13.3% | 3 days | 2 days (Jun 29, 2021) |
| Jun 30, 2021 | Jul 20, 2021 | -11.4% | 13 days | 10 days (Aug 3, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $277.0M
- EPS, diluted (TTM)
- -$1.04
- Revenue (TTM)
- $0
- 52-week range
- $0.44 – $3.04
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $5.2M | $2.2M | $6.6M | $109.2M |
| Gross profit | -$4.6M | $5.2M | $2.2M | $6.6M | $96.1M |
| Operating income | -$94.9M | -$133.8M | -$146.5M | -$138.1M | -$15.0M |
| Net income | -$95.8M | -$130.9M | -$136.7M | -$126.6M | -$9.6M |
| EPS (diluted) | -$1.74 | -$2.27 | -$2.30 | -$1.61 | -$0.11 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $791,000 | $4.2M | $109.2M | $0 | $0 | $0 | $0 | $0 |
| Net income | -$31.2M | -$36.1M | $76.6M | -$32.5M | -$34.4M | -$19.2M | -$21.6M | -$34.5M |
| EPS (diluted) | -$0.37 | -$0.46 | $0.89 | -$0.38 | -$0.40 | -$0.22 | -$0.25 | -$0.17 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$89.0M | $14.1M | -$88.3M | -$110.1M | -$103.9M |
| Capital expenditure | -$45.0M | -$30.6M | -$13.7M | -$154,000 | -$848,000 |
| Free cash flow | -$134.0M | -$16.6M | -$102.1M | -$110.3M | -$104.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $221.6M | $27.2M | $516,000 | $74.6M | $173,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $119.7M
- Total assets
- $287.0M
- Total liabilities
- $54.7M
- Total debt
- $34.6M
- Net debt
- -$15.0M
- Shareholders’ equity
- $232.3M
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 29,354,630
- Days to cover
- 78.64
- Change vs previous report
- -0.6%
FINRA short interest, settlement date Sep 15, 2026.